Camostat mesylate inhibits SARS-CoV-2 activation by TMPRSS2-related proteases and its metabolite GBPA exerts antiviral activity

Mostrar otras versiones (1)

Antiviral therapy is urgently needed to combat the coronavirus disease 2019 (COVID-19) pandemic, which is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The protease inhibitor camostat mesylate inhibits SARS-CoV-2 infection of lung cells by blocking the virus-activating host...

Descripción completa

Detalles Bibliográficos
Autores principales: Hoffmann, Markus, Hofmann-Winkler, Heike, Smith, Joan C., Krüger, Nadine, Sørensen, Lambert K., Søgaard, Ole S., Hasselstrøm, Jørgen Bo, Winkler, Michael, Hempel, Tim, Raich, Lluís, Olsson, Simon, Yamazoe, Takashi, Yamatsuta, Katsura, Mizuno, Hirotaka, Ludwig, Stephan, Noé, Frank, Sheltzer, Jason M., Kjolby, Mads, Pöhlmann, Stefan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cold Spring Harbor Laboratory 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7418737/
https://www.ncbi.nlm.nih.gov/pubmed/32793911
http://dx.doi.org/10.1101/2020.08.05.237651

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7418737/
https://www.ncbi.nlm.nih.gov/pubmed/32793911
http://dx.doi.org/10.1101/2020.08.05.237651

Ejemplares similares